Medicine from the statin group, treatment of hypercholesterolaemia, prevention of cardiovascular accidents, in the form of tablets.
CorVaPro is indicated for:
Treatment of hypercholesterolaemia
Adults, adolescents and children from 6 years of age with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia)
or mixed dyslipidaemia (type IIb) as a supplement to dietary measures in cases where the response to the diet alone and other non-pharmacological treatment (eg. physical activity, weight loss) is unsatisfactory.
Adults, adolescents and children from 6 years of age with homozygous familial hypercholesterolaemia as a supplement to the diet and other hypolipidaemic treatments (eg. LDL apheresis), or alone if these are not recommended.
Prevention of cardiovascular accidents.
Prevention of serious cardiovascular accidents for patients with high estimated risk of a first cardiovascular accident (see section 5.1), in addition to the correction of other risk factors.
The obligation to establish a Publicly Accessible Professional Information Service (PAPIS)
result from Act No. 378/2007 Sb., O léčivech. Information on our products can be
found on the website of the State Institute for Drug Control (SÚKL) in the
Product information (SPC or PIL) is available by clicking on the product name and the
Summary of Product Characteristics (SPC) link.
The Publicly Accessible Professional Information Service (PAPIS) for CorVaPro
is operated by the marketing authorization holder - Pharma-Service International s.r.o., contact: